Spexib 150mg Capsule
Rx RequiredSalt Composition: Ceritinib
Expiry Date: 01/2028
Price on Request
Inclusive of all taxes
10 capsule(s) in a strip
About The Product
Non-small cell lung cancer
- Spexib 150 mg capsule contains ceritinib as a targeted medicine used by adults for treating metastatic non-small-cell lung cancer (NSCLC) that tests positive for an abnormal ALK gene.
- This capsule serves as a kinase inhibitor that blocks the abnormal signal produced by ALK protein in order to minimize tumor growth. Individuals who can take Spexib are those whose disease progression occurs after being treated with crizotinib and who are eligible for first-line treatment.
- The recommended dose of Ceritinib is 450 mg per day in one single dose (3 x 150 mg capsules), which should be taken with food.
- The common adverse effects are diarrhea, nausea, vomiting, abdominal pain, exhaustion, loss of appetite, and weight loss.
- Pregnant or nursing mothers should avoid using this medication, and patients must disclose existing cardiac illnesses (long QT interval) or renal and liver impairments prior to taking it.
Side Effects
Every medicine has some side effects that manage on their own as your body gets used to the medicine, but some people may rarely experience severe side effects. In that case, the patient should contact the doctor immediately. Some side effects of Spexib 150mg Capsule include:
Diarrhea
Nausea and vomiting
Constipation or stomach pain
Decreased appetite and weight loss
Fatigue or weakness
Anemia (low red blood cell count)
Low phosphate levels in the blood
Increased urination
Irregular heartbeat
Cough (with or without mucus)
Fever or chest pain
Difficulty breathing or swallowing
Swelling of the face, lips, tongue, or throat
Severe skin itching, bumps, or rash
Right‑sided abdominal pain (possible liver issues)
Bleeding or easy bruising
Skin rash or irritation
Eye problems such as dryness, irritation, or corneal damage
Respiratory infections
How To Use
- Spexib 150mg Capsule is usually taken once a day as prescribed by the doctor.
- Ceritinib 150mg should be taken with meals to reduce stomach upset and improve absorption.
- Follow your doctor's advice strictly regarding the dosage and duration.
- Swallow the capsule as a whole with a glass of water. Do not crush, chew, or break the capsule.
Safety Advice
The interaction of alcohol with this medicine is still unknown. It is advisable not to consume alcohol while taking medicine and to consult your doctor for further information.
Spexib 150mg Capsule is not recommended during pregnancy as it is unsafe for the developing fetus. Doctors rarely prescribe this medicine in pregnancy in which it will do more good than harm.
Spexib 150mg Capsule is unsafe to use during breastfeeding as it may cause toxicity to the baby.
Spexib 150mg Capsule may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving or operating heavy machinery.
Share your medical history with the doctor in case of kidney issues before taking this medicine.
Share your medical history with the doctor in case of liver disease before taking this medicine.
Missed Doses
- If you forget to take a dose of Spexib 150mg Capsule, consult your doctor.
- Take your missed dose as soon as you remember it, but don’t double up on doses under any circumstances.
- If it’s nearly time for the next dose when you discover that you’ve forgotten one, just wait until the next dose.
FAQs
Spexib 150mg Capsule is an anticancer drug prescribed to treat Non-small cell lung cancer (NSCLC).
References
- Khozin, S., Blumenthal, G. M., Zhang, L., Tang, S., Brower, M., Fox, E., ... & Pazdur, R. (2015). FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase–positive non–small cell lung cancer. Clinical cancer research, 21(11), 2436-2439.
- https://www.cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPrescribingInfo/9Ceritinib.pdf
- Dhillon, S., & Clark, M. (2014). Ceritinib: first global approval. Drugs, 74(11), 1285-1291.
- Kim, D. W., Mehra, R., Tan, D. S., Felip, E., Chow, L. Q., Camidge, D. R., ... & Shaw, A. T. (2016). Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. The lancet oncology, 17(4), 452-463.
- Cooper, M. R., Chim, H., Chan, H., & Durand, C. (2015). Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer. Annals of Pharmacotherapy, 49(1), 107-112.
- Soria, J. C., Tan, D. S., Chiari, R., Wu, Y. L., Paz-Ares, L., Wolf, J., ... & de Castro, G. (2017). First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet, 389(10072), 917-929.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
